- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1751 |
Product Name |
ADT1751-Human Anti-CD3xCD19 Bispecific Antibody |
Isotype |
His |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-CD3 mAb, Anti-CD3 Monoclonal Antibody, CD3 recombinant antibody, Anti-CD3 Bispecific Antibody, Human Anti-CD19 mAb, CD19 recombinant antibody, Anti-CD19 Monoclonal Antibody, Anti-CD19 Bispecific Antibody |
|
Official Symbol |
CD3xCD19 |
Target 1 |
CD3 |
Gene ID 1 |
916 |
Target 2 |
CD19 |
Gene ID 2 |
930 |
Species |
Human |
Drug Name |
Blinatumomab |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
CAS Number |
853426-35-4 |
Chemical Formula |
C2367H3577N649O772S19 |
Molecular Weight |
54.1 KDa |
Product Description |
Blinatumomab is an antineoplastic antibody used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients, as well as those in first or second complete remission with minimal residual disease (MRD). |
Mechanism of Action |
Blinatumomab is a bispecific T-cell engager (BiTE) that targets CD19, an antigen expressed on the surface of B-cells, and CD3, an antigen expressed on the surface of T-cells. B-cell malignancies, such as acute lymphoblastic leukemia (ALL), express high levels of CD19, making it a therapeutic target for the treatment of these conditions. Blinatumomab recruits and activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on both benign and malignant B cells. |
Metabolism |
The metabolic pathway of blinatumomab has not been characterized. As a monoclonal antibody, blinatumomab is expected to be metabolized into small peptides and amino acids via catabolic pathways. |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
PBS, pH 7.4, Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Zugmaier G, Klinger M, Schmidt M, Subklewe M: Clinical overview of anti-CD19 BiTE((R)) and ex vivo data from anti-CD33 BiTE((R)) as examples for retargeting T cells in hematologic malignancies. Mol Immunol. 2015 Oct;67(2 Pt A):58-66. doi: 10.1016/j.molimm.2015.02.033. Epub 2015 Apr 13.
2. Garber K: Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478.
|
FAQ
-
+ -
How do bispecific antibodies compare to CAR-T therapy?
BsAbs act faster, are easier to manufacture, and lack the complexity of cell therapy. However, CAR-T offers durable responses, while BsAbs may require continuous dosing.
-
+ -
How can I obtain COA of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
How is bispecific antibody half-life optimized?
Strategies include Fc engineering, PEGylation, or fusion with albumin-binding domains to prolong circulation time. -
+ -
What are bispecific antibody-drug conjugates (BsADCs)?
BsADCs combine dual targeting with cytotoxic payload delivery, increasing tumor specificity and reducing off-tumor toxicity.